Plus Therapeutics Q1 net loss narrows

Cerenome

15/05/2026 21:16

Overview

U.S. CNS cancer radiopharmaceutical developer's Q1 revenue fell slightly, net loss narrowed sharply

Operating loss widened in Q1 due to CNSide commercial expansion and REYOBIQ trial investment

Company completed $15 mln public offering, increasing cash to support commercialization and clinical programs

Outlook

Company reaffirms 2026 milestone framework and outlook provided in full-year 2025 results

Plus aims to expand U.S. commercial payer coverage for CNSide to over 150 mln covered lives in 2026

Company expects to complete enrollment in ReSPECT-GBM Phase 2 trial; data expected Q1 2027

Result Drivers

COMMERCIAL EXPANSION - Co said higher operating loss was mainly due to scaling up CNSide commercial operations

CLINICAL TRIAL INVESTMENT - Continued investment in REYOBIQ Phase 2 trials contributed to increased operating expenses

PAYER COVERAGE GAINS - Co added new payer agreements for CNSide, expanding coverage to about 81 mln covered lives

Company press release: ID:nGNX3W5LTs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$6.95 mln
Q1 Operating Expenses
$8.15 mln
Q1 Operating Income
-$7.12 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)